When we started exploring what it would look like for brand teams to review their own collaterals before submitting for medical and regulatory approval, we had a clear assumption about where the value would come from.
Faster review cycles. Fewer rounds between marketing and medical. Cleaner first submissions that move through the process with less friction. That was the expected outcome. And it did happen. When basic issues were caught before submission, the review process shortened. Medical teams could focus on the substantive questions instead of flagging missing superscripts and unsupported claims.
But that turned out to be the smaller story.
The bigger shift was in what reached the field
When brand teams could see their own gaps before sending materials forward, something unexpected happened. They did not just fix the compliance and accuracy issues. Those were the obvious corrections. The missing reference gets added. The unsupported claim gets qualified or removed. The prohibited term gets replaced.
What surprised us was what happened next. Once the surface level issues were addressed, the brand team started looking at the collateral differently. With the regulatory and accuracy concerns no longer occupying their attention, they began noticing the strategic weaknesses.
They saw where the key message was buried on page three instead of leading the conversation. Where two competing claims were fighting for attention on the same page. Where the visual flow did not support the narrative the MR was supposed to deliver. Where the collateral was technically correct but strategically weak.
These are not things a compliance review catches. They are not things a medical review is designed to catch. They are the gap between a collateral that is correct and a collateral that is effective. And that gap only becomes visible when the basic issues are out of the way.
What changed in the output
The collateral that eventually went through the approval process and reached print was not just cleaner. It was a fundamentally different piece of communication. The messaging was tighter. The visual hierarchy was clearer. The MR had a better story to tell.
And that difference did not just improve one doctor interaction. It multiplied across every MR carrying that collateral, across every doctor call they made with it, across every territory in the field.
How the marketing-medical conversation changed
When the brand team caught the basic issues themselves before submission, medical stopped spending time on things the brand team could have identified on their own. The review conversation moved to a different level. Instead of debating whether a particular claim was adequately referenced, they were discussing whether the clinical narrative was the strongest way to position the product.
That is the conversation marketing and medical should always be having. But they rarely get to it because the basic issues consume too much of the review window. When those issues are resolved before submission, the window opens for the kind of dialogue that actually improves the collateral.
The compounding effect nobody expected
There was one more effect we did not expect. A compounding effect.
Teams that saw their own gaps once started producing better first drafts in the next cycle. The brand manager who realised that their visual aid buried the key message on page three did not make the same mistake again. The team that noticed their comparison chart lacked adequate citations started building the citation framework into the creative brief.
Over two or three cycles, the quality of first drafts improved noticeably. The review rounds shortened not because the process changed but because the input quality improved. The brand team was learning from its own gaps in a way that no training session or SOP document could replicate.
Where the real value sits
Faster approvals matter. In an industry where cycle meeting deadlines are unforgiving and printing windows are tight, any reduction in review time is valuable. But the faster approvals turned out to be the secondary benefit.
The primary value was something different. Stronger collaterals reaching the field. Collaterals where the doctor actually remembers the key message after the MR leaves the room. Collaterals where the MR is confident in the story they are telling. Collaterals that are not just compliant but compelling.
That difference, multiplied across hundreds of MRs making thousands of calls, is where the real value sits. Not in the days saved during the review cycle. In the impact created in the doctor’s chamber.